Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 277
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
9/20/2005
1.
Phase III Randomized Study of Topotecan vs Observation Following CDDP/VP-16 for Extensive Stage Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
ECOG-E7593
E7593
Last Modified:
11/1/1994
2.
Phase III Randomized, Open-Label, Multicenter Study of Topotecan vs Paclitaxel as Single-Agent, Second-Line Therapy for Platinum-Refractory Advanced Epithelial Ovarian Carcinoma (Summary Last Modified 11/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
SB-104864/039
NCI-V94-0490
Last Modified:
6/1/1997
3.
Phase III Randomized Study of TOPO vs CAV (CTX/DOX/VCR) as Second-Line Therapy for Recurrent Small Cell Lung Cancer (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
SB-104864/090
NCI-V95-0673
Last Modified:
6/1/1999
4.
Phase III, Randomized, Open-Label, Comparative Study of Liposomal Doxorubicin (DOXIL) versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First Line, Platinum Based Chemotherapy (Summary Last Modified 06/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
SEQUUS-30-49
NCI-V97-1257
Last Modified:
5/31/2007
 
First Published:
8/1/1999
5.
Phase III Randomized Study of Oral Versus Intravenous Topotecan in Patients With Limited or Extensive Small Cell Lung Cancer That Has Relapsed Following First Line Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
CWRU-SKF-1598
SB-104864-A/396, NCI-G99-1524, NCT00003917
Last Modified:
7/10/2008
 
First Published:
8/1/1999
6.
Phase III Randomized Study of Cisplatin Only Versus Cisplatin Plus Topotecan Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
GOG-0179
ECOG-G0179, NCT00003945
Last Modified:
10/3/2007
 
First Published:
8/1/1999
7.
Phase III Randomized Study of Vincristine, Dactinomycin, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan, and Cyclophosphamide in Patients With Intermediate-Risk, Previously Untreated Rhabdomyosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
Under 50
NCI
COG-D9803
CCG-D9803, POG-D9803, IRS-D9803, NCT00003958, D9803
Last Modified:
10/3/2007
 
First Published:
1/1/2000
8.
Phase III Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplantation After Dose-Intensive Induction Chemotherapy in Patients With Newly Diagnosed High Risk Neuroblastoma or Ganglioneuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
30 and under
NCI
COG-A3973
CCG-A3973, POG-A3973, CCG-39703, FHCRC-1631.00, NCT00004188, A3973
Last Modified:
6/12/2007
 
First Published:
11/1/2000
9.
Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Topotecan in Patients With Stage IIB, III, or IV Ovarian Epithelial Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
AGOSG-OVAR-7
NCI-V00-1602, NCT00006454
Last Modified:
8/19/2008
 
First Published:
3/1/2001
10.
Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Gemcitabine, Doxorubicin HCl Liposome, or Topotecan in Patients With Stage III or IV Ovarian Epithelial or Serous Primary Peritoneal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Any age
NCI
GOG-0182
SWOG-G0182, MRC-ICON5, ECOG-G0182, NCT00011986
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute